THE FUTURE OF NON-INVASIVE RESPIRATORY MONITORING
01
No tubes. No wires.
Non-invasively monitors patient’s breathing, gives reliable alerts for deteriorating volumes, apnea and obstructive breathing
02
Cost-effective
Monitors breathing at a fraction of the cost of existing monitoring technologies by utilizing off-the-shelf hardware.
03
Intuitive & Simple
Straight-forward to use and interpret by all medical staff. Output consists of standard respiratory parameters.
MEET BREATHEVISION
OUR STORY
BreatheVision was founded in 2013 on the need to develop a simple method for early detection of breathing deterioration in patients under conscious sedation... The founders built on their expertise in machine vision and missile navigation algorithms to invent a way to quantify breathing through analyzing chest micro-movements based on low-cost off the shelf hardware.
OUR VISION
To improve patient safety by monitoring essential breathing parameters through machine learning technology and providing immediate warning.
OUR PRODUCT
Our first product, the SafeSed monitoring system, was developed for medical staff to continuously monitor respiration for post anesthesia sedated patients.
PROSPECTIVE TARGET MARKETS
COVID-19 respiratory monitoring
Post-anesthesia
monitoring
Procedural
sedation
Remote and home monitoring
Neonatal
hospital
monitoring
CLINICAL VALIDATION
BreatheVision performed clinical validation of the SafeSed monitoring system at Meir Medical Center (Kfar Saba, Israel) and Tel-Aviv Medical Center.
The SafeSed system was compared to conventional means of respiratory monitoring:
-
Colonoscopy - SafeSed vs. Capnography
-
Operation Room - SafeSed vs. Anesthesia Machine
-
Healthy Volunteers - SafeSed vs. Spirometry
-
PACU post anesthesia - SafeSed vs. Pulse Oximetry and Clinical Logs
SafeSed signal vs. Capnograph signal
OUR TEAM
Menashe Terem
CEO
Ditza Aurebach
Founder
Ofer Leizerovich
Omri Cohen
Project Manager
Ziv Geva
CTO
Omri Tzur
Clinical Project Manager
Avi Kriheli
Program Manager
Ofer Orgal
Menashe Terem, MA
CEO & Co-Founder
Former executive at El-Al Airlines who also led several medical device companies into OTC and professional markets worldwide.
Ditza Auerbach, PhD
Founder
Physicist experienced in leading imaging and machine learning R&D at Aspect Imaging and Applied Materials.
Ziv Geva
CTO
Prof. Ilan Shimshoni
Scientific Advisor
Professor of Information Systems at the Computer Science Department at Technion, University of Haifa (Israel)
MEDICAL NEED
Adverse events associated with sedation
“Drug-induced respiratory depression is the primary cause of morbidity associated with sedation and analgesia”
American Society of Gastroenterology Nurses and Associates 2016
"…hospitals are expected to address monitoring for …respiratory
depression related to opioids for post-operative patients…. monitoring of ventilation may warrant … to assess breathing"
Centers for Medicare & Medicaid Services (CMS), 2014
Current monitoring methods
“Staff should … not to rely on pulse oximetry alone because pulse oximetry can suggest adequate oxygen saturation in patients … experiencing respiratory depression, especially when supplemental oxygen is being used.”
The Joint Commission Sentinel Event Alert, 2012
“Capnography devices often indicate problems where none exist… At worst, frequent alarm errors may lead to alarm fatigue and a tendency to ignore valid alarms.”
American Society for Gastrointestinal Endoscopy, 2012
“No studies have been published on the effectiveness of capnography on clinically important outcomes (rescue team activation, ICU transfers, or mortality). Etco2 may not accurately reflect the Paco2 in nonintubated patients in the setting of low-tidal volume breathing or mouth breathing... Capnography may require extra training of staff members before implementation.”
Anesthesia & Analgesia; Vol. 125 Issue 6, 2017
Future monitoring methods
“Quantitative monitoring of the volume of expired gas is strongly encouraged.”
American Society of Anesthesiologists, 2015
SafeSed has been developed for medical staff, to continuously monitor respiration.
OUR
TECHNOLOGY
SafeSed recognizes deterioration in patient's breathing that requires immediate medical attention.
Apnea
Obstructive
Shallow
SafeSed - No Tubes, No Wires
Simply Brilliant!
NEWS
1st clinical trial for SafeSed in the Gastro clinic began recruiting at Meir Medical Centre, Israel.
DEC.
2016
DEC.
2nd US Patent granted for the SafeSed system.
2019
1st US Patent granted for the SafeSed system.
OCT.
2017
Completed development of a Central Monitoring System for remote monitoring of multiple COVID-19 patients simultaneously.
JUN.
2020
Successful FDA Pre-Submission meeting for the SafeSed device.
APR.
2018
FEB.
Healthy Volunteers Clinical Trial for performance and accuracy evaluation of SafeSed at Meir Medical Centre, Israel has been completed successfully.
2020
Clinical Validation Trial for Volume determination by SafeSed vs. Anesthesia machine at Meir Medical Centre, Israel has completed successfully.
AUG.
2018
APR.
4th Grant from the Israel Innovation Authority for COVID-19 Pilot.
2020
First round of crowd-funding completed. Second round during Q1 2020. Total of 4.5M NIS raised.
AUG.
2019
OCT.
2020
Pilot in PACU for respiratory deterioration monitoring and prediction by SafeSed began recruiting at Tel-Aviv Medical Centre, Israel.
LINKS
ABOUT
Tel: +972-(0) 8-672-0512
BreatheVision Ltd.
6 Harash st.
Nes Ziona 7403113, Israel